"Radioimmunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
| Descriptor ID |
D016499
|
| MeSH Number(s) |
E02.095.465.425.750 E02.186.750 E02.815.520
|
| Concept/Terms |
Radioimmunotherapy- Radioimmunotherapy
- Radioimmunotherapies
- Immunoradiotherapy
- Immunoradiotherapies
|
Below are MeSH descriptors whose meaning is more general than "Radioimmunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Radioimmunotherapy".
This graph shows the total number of publications written about "Radioimmunotherapy" by people in this website by year, and whether "Radioimmunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Radioimmunotherapy" by people in Profiles.
-
Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19. J Nucl Med. 2021 07 01; 62(7):1020.
-
Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials. Int Immunopharmacol. 2018 Aug; 61:363-375.
-
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 08; 18(1):646.
-
Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy. 2018 06; 10(8):699-711.
-
Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. Immunotherapy. 2017 03; 9(5):423-433.